JP2001520511A5 - - Google Patents

Download PDF

Info

Publication number
JP2001520511A5
JP2001520511A5 JP1997521454A JP52145497A JP2001520511A5 JP 2001520511 A5 JP2001520511 A5 JP 2001520511A5 JP 1997521454 A JP1997521454 A JP 1997521454A JP 52145497 A JP52145497 A JP 52145497A JP 2001520511 A5 JP2001520511 A5 JP 2001520511A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997521454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001520511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/019454 external-priority patent/WO1997020575A1/en
Publication of JP2001520511A publication Critical patent/JP2001520511A/ja
Publication of JP2001520511A5 publication Critical patent/JP2001520511A5/ja
Ceased legal-status Critical Current

Links

JP52145497A 1995-12-08 1996-12-06 向標的性アデノウイルス・ベクター Ceased JP2001520511A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US837595P 1995-12-08 1995-12-08
US60/008,375 1995-12-08
US2016396P 1996-06-20 1996-06-20
US60/020,163 1996-06-20
PCT/US1996/019454 WO1997020575A1 (en) 1995-12-08 1996-12-06 Targeted adenovirus vectors

Publications (2)

Publication Number Publication Date
JP2001520511A JP2001520511A (ja) 2001-10-30
JP2001520511A5 true JP2001520511A5 (https=) 2004-11-04

Family

ID=26678130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52145497A Ceased JP2001520511A (ja) 1995-12-08 1996-12-06 向標的性アデノウイルス・ベクター

Country Status (5)

Country Link
US (1) US5871727A (https=)
EP (1) EP0866721A4 (https=)
JP (1) JP2001520511A (https=)
AU (1) AU726544B2 (https=)
WO (1) WO1997020575A1 (https=)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
AUPO023496A0 (en) * 1996-05-31 1996-06-27 Commonwealth Scientific And Industrial Research Organisation Modified small RNA viruses
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP0998576B1 (en) 1997-06-23 2007-10-31 The University of Saskatchewan Method for producing a recombinant bovine adenovirus vector
FR2770537B1 (fr) 1997-11-03 2001-06-01 Commissariat Energie Atomique Vecteur peptidique de transfection, composition le contenant et leurs applications
CA2317941A1 (en) * 1998-01-16 1999-07-22 Genzyme Corporation Adenoviral vectors with modified capsid proteins
IL137681A0 (en) * 1998-02-06 2001-10-31 Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
IL137730A0 (en) * 1998-02-17 2001-10-31 Uab Research Foundation Modified adenovirus containing a fiber replacement protein
AU3358999A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1112372A1 (en) 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
US6841540B1 (en) * 1998-09-29 2005-01-11 The Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and B cells
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6649396B1 (en) * 1999-02-05 2003-11-18 Uab Research Foundation Fiber receptor-independent system for the propagation of adenoviral vectors
AU767904B2 (en) * 1999-05-12 2003-11-27 Uab Research Foundation, The Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
CA2378324A1 (en) * 1999-07-06 2001-01-11 Leif Lindholm Recombinant adenovirus
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
WO2001021216A1 (en) * 1999-09-24 2001-03-29 The Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
WO2001028569A1 (en) 1999-10-15 2001-04-26 Canji, Inc. Targeted vectors
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
WO2001058458A1 (en) 2000-02-08 2001-08-16 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
JP2003534805A (ja) 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン 変化した親和性を有する改変ウシアデノウイルス
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US6762031B2 (en) 2000-06-16 2004-07-13 University Of Medicine And Dentistry Of New Jersey Targeting viral vectors to specific cells
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
AU2002250081A1 (en) * 2001-02-14 2002-08-28 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
CA2445626A1 (en) * 2001-04-17 2002-10-24 Vectorlogics, Inc. Mosaic adenoviral vectors
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
WO2003062400A2 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
CA2474728A1 (en) * 2002-02-06 2003-08-14 Johns Hopkins University School Of Medicine Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
KR101021387B1 (ko) * 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US7608449B2 (en) * 2003-05-14 2009-10-27 The Regents Of The University Of California Methods and compositions related to high-titer pseudotyped retroviruses
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
WO2005092286A2 (en) * 2004-03-29 2005-10-06 The University Of Houston System Metallic nano-particles and discrete polymer-coated nano-particles
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
US20070212298A1 (en) * 2004-08-25 2007-09-13 Prefix Suffix Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
JP2008519642A (ja) * 2004-11-12 2008-06-12 ケーピーイー リミテッド ナノ粒子を介した超音波治療および診断影像法
EP1856526A4 (en) 2005-01-20 2008-11-12 Univ Rochester THIOREDOXIN-INTERACTING PROTEIN (TXNIP) AS REGULATOR OF VASCULAR FUNCTION
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
CN101460055A (zh) * 2006-04-07 2009-06-17 得克萨斯大学体系董事会 和腺伴随病毒-噬菌体颗粒相关的方法和组合物
WO2008086386A2 (en) * 2007-01-09 2008-07-17 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2008095168A2 (en) * 2007-02-01 2008-08-07 University Of Chicago Compositions and methods related to a recombinant adenoviral vector that targets il 13 receptors
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
EA201270607A1 (ru) 2009-11-09 2012-09-28 Генвек, Инк. Аденовирус обезьян и способы его использования
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
EP2658567A4 (en) 2010-12-28 2014-09-24 Univ Rochester METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
EP2908853B1 (en) 2012-10-21 2018-12-05 University Of Rochester Thy1 (cd90) as a therapy to control adipose tissue accumulation
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
EP3436591B1 (en) * 2016-03-31 2023-01-04 The European Molecular Biology Laboratory Adenoviral coat protein derived delivery vehicles
US11246868B2 (en) 2016-04-26 2022-02-15 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
CN111511484A (zh) 2017-11-04 2020-08-07 索纳纳米技术公司 金属纳米颗粒及制备所述金属纳米颗粒的方法
EP3927833A4 (en) 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ES2249761T3 (es) * 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber

Similar Documents

Publication Publication Date Title
JP2000500228A5 (https=)
JP2000500445A5 (https=)
JP2000500440A5 (https=)
JP2000500327A5 (https=)
JP2001520511A5 (https=)
JP2000500145A5 (https=)
JP2000500155A5 (https=)
JP2000500406A5 (https=)
JP2000500361A5 (https=)
JP2000500322A5 (https=)
JP2000513389A5 (https=)
JP2000500258A5 (https=)
JP2000500342A5 (https=)
JP2000500192A5 (https=)
JPH11510142A5 (https=)
JP2000500226A5 (https=)
JP2000500166A5 (https=)
JP2000500397A5 (https=)
JP2000500407A5 (https=)
JPH11513837A5 (https=)
JP2000500125A5 (https=)
JP2000500346A5 (https=)
JP2000500257A5 (https=)
JP2001519889A5 (https=)
JP2000500429A5 (https=)